384 related articles for article (PubMed ID: 22745160)
1. Activation of the p53 pathway by small-molecule-induced MDM2 and MDMX dimerization.
Graves B; Thompson T; Xia M; Janson C; Lukacs C; Deo D; Di Lello P; Fry D; Garvie C; Huang KS; Gao L; Tovar C; Lovey A; Wanner J; Vassilev LT
Proc Natl Acad Sci U S A; 2012 Jul; 109(29):11788-93. PubMed ID: 22745160
[TBL] [Abstract][Full Text] [Related]
2. Medicinal Chemistry Strategies to Disrupt the p53-MDM2/MDMX Interaction.
Lemos A; Leão M; Soares J; Palmeira A; Pinto M; Saraiva L; Sousa ME
Med Res Rev; 2016 Sep; 36(5):789-844. PubMed ID: 27302609
[TBL] [Abstract][Full Text] [Related]
3. Elevated MDM2 boosts the apoptotic activity of p53-MDM2 binding inhibitors by facilitating MDMX degradation.
Xia M; Knezevic D; Tovar C; Huang B; Heimbrook DC; Vassilev LT
Cell Cycle; 2008 Jun; 7(11):1604-12. PubMed ID: 18520179
[TBL] [Abstract][Full Text] [Related]
4. Efficient p53 activation and apoptosis by simultaneous disruption of binding to MDM2 and MDMX.
Hu B; Gilkes DM; Chen J
Cancer Res; 2007 Sep; 67(18):8810-7. PubMed ID: 17875722
[TBL] [Abstract][Full Text] [Related]
5. Discovery of novel dual inhibitors against Mdm2 and Mdmx proteins by in silico approaches and binding assay.
Golestanian S; Sharifi A; Popowicz GM; Azizian H; Foroumadi A; Szwagierczak A; Holak TA; Amanlou M
Life Sci; 2016 Jan; 145():240-6. PubMed ID: 26746660
[TBL] [Abstract][Full Text] [Related]
6. Induction of p53 expression and apoptosis by a recombinant dual-target MDM2/MDMX inhibitory protein in wild-type p53 breast cancer cells.
Geng QQ; Dong DF; Chen NZ; Wu YY; Li EX; Wang J; Wang SM
Int J Oncol; 2013 Dec; 43(6):1935-42. PubMed ID: 24126697
[TBL] [Abstract][Full Text] [Related]
7. Targeting RING domains of Mdm2-MdmX E3 complex activates apoptotic arm of the p53 pathway in leukemia/lymphoma cells.
Wu W; Xu C; Ling X; Fan C; Buckley BP; Chernov MV; Ellis L; Li F; Muñoz IG; Wang X
Cell Death Dis; 2015 Dec; 6(12):e2035. PubMed ID: 26720344
[TBL] [Abstract][Full Text] [Related]
8. DIMP53-1: a novel small-molecule dual inhibitor of p53-MDM2/X interactions with multifunctional p53-dependent anticancer properties.
Soares J; Espadinha M; Raimundo L; Ramos H; Gomes AS; Gomes S; Loureiro JB; Inga A; Reis F; Gomes C; Santos MMM; Saraiva L
Mol Oncol; 2017 Jun; 11(6):612-627. PubMed ID: 28296148
[TBL] [Abstract][Full Text] [Related]
9. Molecular basis for the inhibition of p53 by Mdmx.
Popowicz GM; Czarna A; Rothweiler U; Szwagierczak A; Krajewski M; Weber L; Holak TA
Cell Cycle; 2007 Oct; 6(19):2386-92. PubMed ID: 17938582
[TBL] [Abstract][Full Text] [Related]
10. MDM2/X inhibitors under clinical evaluation: perspectives for the management of hematological malignancies and pediatric cancer.
Tisato V; Voltan R; Gonelli A; Secchiero P; Zauli G
J Hematol Oncol; 2017 Jul; 10(1):133. PubMed ID: 28673313
[TBL] [Abstract][Full Text] [Related]
11. Systematic mutational analysis of peptide inhibition of the p53-MDM2/MDMX interactions.
Li C; Pazgier M; Li C; Yuan W; Liu M; Wei G; Lu WY; Lu W
J Mol Biol; 2010 Apr; 398(2):200-13. PubMed ID: 20226197
[TBL] [Abstract][Full Text] [Related]
12. Affinity-based screening of MDM2/MDMX-p53 interaction inhibitors by chemical array: identification of novel peptidic inhibitors.
Noguchi T; Oishi S; Honda K; Kondoh Y; Saito T; Kubo T; Kaneda M; Ohno H; Osada H; Fujii N
Bioorg Med Chem Lett; 2013 Jul; 23(13):3802-5. PubMed ID: 23726030
[TBL] [Abstract][Full Text] [Related]
13. Structural basis for high-affinity peptide inhibition of p53 interactions with MDM2 and MDMX.
Pazgier M; Liu M; Zou G; Yuan W; Li C; Li C; Li J; Monbo J; Zella D; Tarasov SG; Lu W
Proc Natl Acad Sci U S A; 2009 Mar; 106(12):4665-70. PubMed ID: 19255450
[TBL] [Abstract][Full Text] [Related]
14. Searching for Dual Inhibitors of the MDM2-p53 and MDMX-p53 Protein-Protein Interaction by a Scaffold-Hopping Approach.
Zaytsev A; Dodd B; Magnani M; Ghiron C; Golding BT; Griffin RJ; Liu J; Lu X; Micco I; Newell DR; Padova A; Robertson G; Lunec J; Hardcastle IR
Chem Biol Drug Des; 2015 Aug; 86(2):180-9. PubMed ID: 25388787
[TBL] [Abstract][Full Text] [Related]
15. An Update on MDMX and Dual MDM2/X Inhibitors.
Espadinha M; Barcherini V; Lopes EA; Santos MMM
Curr Top Med Chem; 2018; 18(8):647-660. PubMed ID: 29866007
[TBL] [Abstract][Full Text] [Related]
16. MDM2/MDMX inhibitor peptide: WO2008106507.
Macchiarulo A; Pellicciari R
Expert Opin Ther Pat; 2009 May; 19(5):721-6. PubMed ID: 19441944
[TBL] [Abstract][Full Text] [Related]
17. Abnormal MDMX degradation in tumor cells due to ARF deficiency.
Li X; Gilkes D; Li B; Cheng Q; Pernazza D; Lawrence H; Lawrence N; Chen J
Oncogene; 2012 Aug; 31(32):3721-32. PubMed ID: 22120712
[TBL] [Abstract][Full Text] [Related]
18. Designing dual inhibitors of Mdm2/MdmX: Unexpected coupling of water with gatekeeper Y100/99.
Lee XA; Verma C; Sim AYL
Proteins; 2017 Aug; 85(8):1493-1506. PubMed ID: 28425639
[TBL] [Abstract][Full Text] [Related]
19. Efficient reactivation of p53 in cancer cells by a dual MdmX/Mdm2 inhibitor.
Qin L; Yang F; Zhou C; Chen Y; Zhang H; Su Z
J Am Chem Soc; 2014 Dec; 136(52):18023-33. PubMed ID: 25453499
[TBL] [Abstract][Full Text] [Related]
20. Identification and characterization of the first small molecule inhibitor of MDMX.
Reed D; Shen Y; Shelat AA; Arnold LA; Ferreira AM; Zhu F; Mills N; Smithson DC; Regni CA; Bashford D; Cicero SA; Schulman BA; Jochemsen AG; Guy RK; Dyer MA
J Biol Chem; 2010 Apr; 285(14):10786-96. PubMed ID: 20080970
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
